Fig. 3.
Fig. 3. Expression levels of. / DNMTs in normal cells and individual leukemia cases measured by competitive PCR. Expression levels of DNMT1(A,D), 3A (B,E), and 3B (C,F) in CD34+ cells, leukemia cell lines, AML, and CML were assayed by competitive PCR. The levels of DNMTs were displayed as in Figure 2, but normalization was done by using the levels of eitherGAPDH (A-C) or PCNA (D-F). Lane 1 shows the mean value of the levels in normal bone marrow cells; lanes 2-6, CD34+ cells; lane 7, EBV-transformed B-cell line; lane 8, HL60; lane 9, KU812; lane 10, K562; lane 11, AML (FAB subtype M0); lanes 12 and 13, AML (M1); lanes 14-24, AML (M2); lanes 25-28, AML (M3); lanes 29-31, AML (M4); lane 32, AML (M5); lanes 33 and 34, AML (M6); lanes 35 and 36, AML (M7); lanes 37-39, AML (mixed lineage); lanes 40-47, CML (chronic phase); lanes 48-52, CML (myeloid crisis); lanes 53-56, CML (lymphoid crisis).

Expression levels of

DNMTs in normal cells and individual leukemia cases measured by competitive PCR. Expression levels of DNMT1(A,D), 3A (B,E), and 3B (C,F) in CD34+ cells, leukemia cell lines, AML, and CML were assayed by competitive PCR. The levels of DNMTs were displayed as in Figure 2, but normalization was done by using the levels of eitherGAPDH (A-C) or PCNA (D-F). Lane 1 shows the mean value of the levels in normal bone marrow cells; lanes 2-6, CD34+ cells; lane 7, EBV-transformed B-cell line; lane 8, HL60; lane 9, KU812; lane 10, K562; lane 11, AML (FAB subtype M0); lanes 12 and 13, AML (M1); lanes 14-24, AML (M2); lanes 25-28, AML (M3); lanes 29-31, AML (M4); lane 32, AML (M5); lanes 33 and 34, AML (M6); lanes 35 and 36, AML (M7); lanes 37-39, AML (mixed lineage); lanes 40-47, CML (chronic phase); lanes 48-52, CML (myeloid crisis); lanes 53-56, CML (lymphoid crisis).

Close Modal

or Create an Account

Close Modal
Close Modal